Suppliers and packagers for generic pharmaceutical drug: LEVETIRACETAM

LEVETIRACETAM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ucb Inc	KEPPRA	levetiracetam	INJECTABLE;INTRAVENOUS	021872	NDA	UCB, Inc.	50474-002-63	10 VIAL, SINGLE-USE in 1 CARTON (50474-002-63) / 5 mL in 1 VIAL, SINGLE-USE	2006-08-23
Eugia Pharma	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	204312	ANDA	Eugia US LLC	55150-177-05	10 VIAL, SINGLE-DOSE in 1 CARTON (55150-177-05) / 5 mL in 1 VIAL, SINGLE-DOSE	2016-02-01
Fresenius Kabi Usa	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	090876	ANDA	Fresenius Kabi USA, LLC	63323-400-05	10 VIAL, SINGLE-USE in 1 TRAY (63323-400-05) / 5 mL in 1 VIAL, SINGLE-USE (63323-400-01)	2015-08-13
Fresenius Kabi Usa	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	090876	ANDA	Fresenius Kabi USA, LLC	63323-400-44	10 VIAL, SINGLE-USE in 1 TRAY (63323-400-44) / 5 mL in 1 VIAL, SINGLE-USE (63323-400-41)	2015-08-13
Hainan Poly Pharm	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	209781	ANDA	TAGI Pharma, Inc.	51224-013-10	10 VIAL, SINGLE-USE in 1 CARTON (51224-013-10) / 5 mL in 1 VIAL, SINGLE-USE	2018-11-30
Hainan Poly Pharm	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	209781	ANDA	TAGI Pharma, Inc.	51224-013-25	25 VIAL, SINGLE-USE in 1 CARTON (51224-013-25) / 5 mL in 1 VIAL, SINGLE-USE	2018-11-30
Hainan Poly Pharm	LEVETIRACETAM	levetiracetam	INJECTABLE;INTRAVENOUS	209781	ANDA	Method Pharmaceuticals, LLC	58657-860-01	1 VIAL, SINGLE-DOSE in 1 CARTON (58657-860-01) / 5 mL in 1 VIAL, SINGLE-DOSE (58657-860-00)	2025-12-15

Levetiracetam: Global Supply Chain Analysis and Patent Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain and patent landscape for Levetiracetam, an antiepileptic drug. The analysis identifies key suppliers, examines patent expirations, and assesses potential shifts in market dynamics based on intellectual property.

What is Levetiracetam and its Market Significance?

Levetiracetam is a second-generation antiepileptic drug (AED) that works by inhibiting specific ion channels and neurotransmitter pathways in the brain. Its efficacy in treating various seizure types, coupled with a generally favorable tolerability profile, has established it as a widely prescribed medication. The global market for Levetiracetam is substantial, driven by a high prevalence of epilepsy worldwide.

The market is characterized by both branded and generic competition. The primary branded product, Keppra®, developed by UCB Pharma, has experienced significant market penetration. However, as patents have expired, a robust generic market has emerged, increasing accessibility and driving down average selling prices.

Key Market Drivers:

• Epilepsy Prevalence: According to the World Health Organization, epilepsy is a neurological disorder that affects approximately 50 million people worldwide. This large patient population directly fuels demand for antiepileptic medications like Levetiracetam.
• Generic Competition: The expiration of key patents for Keppra® has led to the introduction of numerous generic Levetiracetam products. This competition has expanded market access and made the drug more affordable.
• Therapeutic Advantages: Levetiracetam is often favored for its relatively rapid absorption, predictable pharmacokinetics, and a lower incidence of drug-drug interactions compared to some older AEDs.
• Expanding Indications: While primarily used for focal-onset seizures and myoclonic seizures in epilepsy, ongoing research may explore additional therapeutic applications, potentially broadening its market.

Who are the Primary Manufacturers and Suppliers of Levetiracetam?

The supply chain for Levetiracetam involves active pharmaceutical ingredient (API) manufacturers and finished dosage form (FDF) manufacturers. The landscape includes both originator companies and a significant number of generic pharmaceutical companies.

Active Pharmaceutical Ingredient (API) Suppliers:

The production of Levetiracetam API is concentrated among several key global manufacturers, primarily located in India and China, which are dominant hubs for generic API production.

• Teva Pharmaceutical Industries Ltd. (Israel): A major global pharmaceutical company with significant API manufacturing capabilities, including for Levetiracetam.
• Dr. Reddy's Laboratories Ltd. (India): A leading Indian pharmaceutical company with a strong presence in API manufacturing and a broad portfolio of generic drugs.
• Sun Pharmaceutical Industries Ltd. (India): One of India's largest pharmaceutical companies, with extensive API production capacity.
• Mylan N.V. (now part of Viatris) (USA/Netherlands): A prominent global generic and specialty pharmaceuticals company.
• Torrent Pharmaceuticals Ltd. (India): An Indian multinational specializing in generic and branded pharmaceuticals, including APIs.
• Hetero Labs Ltd. (India): A major Indian pharmaceutical company known for its API production and contract manufacturing services.
• Lupin Limited (India): Another significant Indian pharmaceutical company with substantial API manufacturing operations.
• Aurobindo Pharma Limited (India): A vertically integrated pharmaceutical company with a strong focus on API development and manufacturing.

Comparison of API Production Centers:

Region	Dominance Factors	Cost Structure	Regulatory Environment
India	High volume, cost-efficiency, established infrastructure, skilled workforce	Low to moderate	Stringent, but well-established for export markets
China	Large-scale production, competitive pricing, growing regulatory oversight	Low	Increasingly stringent, with focus on environmental compliance
Europe	Specialized production, high quality, higher cost	Moderate to high	Highly regulated, stringent quality standards
North America	Primarily for domestic market, higher cost, advanced technology	High	Highly regulated, stringent quality standards

Finished Dosage Form (FDF) Manufacturers:

FDF manufacturers procure Levetiracetam API and formulate it into tablets, oral solutions, and intravenous solutions. This segment includes a wide array of global and regional generic drug companies.

• UCB Pharma (Belgium): The originator of Levetiracetam (Keppra®).
• Teva Pharmaceutical Industries Ltd. (Israel): A significant producer of generic Levetiracetam FDF.
• Sun Pharmaceutical Industries Ltd. (India): A major player in generic FDF manufacturing.
• Dr. Reddy's Laboratories Ltd. (India): Produces generic Levetiracetam formulations.
• Mylan N.V. (USA/Netherlands): Offers generic Levetiracetam products.
• Viatris Inc. (USA): Formed by the merger of Viatris and Mylan, a significant global provider of generic medications.
• Aurobindo Pharma Limited (India): Manufactures and markets generic Levetiracetam FDF.
• Cipla Limited (India): An Indian multinational pharmaceutical company producing generic drugs.
• Hikma Pharmaceuticals PLC (UK): A global pharmaceutical group focused on injectables and generics.

Geographic Distribution of FDF Manufacturing:

The manufacturing of Levetiracetam finished dosage forms is globally distributed, with significant production capacity in North America, Europe, and Asia, catering to regional market demands and regulatory requirements.

What is the Patent Landscape for Levetiracetam?

The patent landscape for Levetiracetam is largely defined by the expiration of primary patents protecting the molecule and its initial formulations. The innovator, UCB Pharma, held key patents that have now expired, paving the way for widespread generic competition.

Key Patent Expirations:

• US Patent 5,597,931: This patent, covering the compound Levetiracetam itself, was a foundational patent for UCB Pharma. It expired in 2016.
• US Patent 6,258,827: This patent related to specific polymorphs of Levetiracetam and expired around 2019.
• Various Formulation and Method of Use Patents: UCB Pharma also secured patents covering different formulations (e.g., extended-release versions) and methods of use. These patents have also expired or are nearing expiration, further opening the market.

Impact of Patent Expirations:

The expiration of core patents for Levetiracetam has had a transformative effect on the market:

• Generic Entry: It allowed numerous pharmaceutical companies to launch generic versions of Levetiracetam, leading to increased competition.
• Price Erosion: The influx of generic products has significantly reduced the average selling price of Levetiracetam, making it more accessible to patients.
• Market Share Shift: The market share of the branded product, Keppra®, has decreased substantially as generic alternatives gained traction.

Ongoing Patent Activity:

While the primary patents have expired, there can still be active patents related to:

• New Formulations: Development of novel drug delivery systems, such as improved extended-release formulations or combination therapies.
• New Polymorphs: Discovery and patenting of different crystalline forms of Levetiracetam that may offer advantages in stability or bioavailability.
• Manufacturing Processes: Patents covering novel or more efficient methods of synthesizing Levetiracetam API.
• New Indications: Patents for the use of Levetiracetam in treating conditions beyond epilepsy, if research proves successful.

These secondary patents can create niche market opportunities or lead to "evergreening" strategies, though their impact on the broad Levetiracetam market is less significant than the initial compound patent.

Key Patent Holders (Historical):

• UCB Pharma S.A.

Databases for Patent Searching:

• United States Patent and Trademark Office (USPTO)
• European Patent Office (EPO)
• World Intellectual Property Organization (WIPO) - Patentscope
• National and Regional Patent Offices (e.g., Indian Patent Office)

What are the Regulatory Considerations for Levetiracetam Supply?

The manufacturing and distribution of Levetiracetam are subject to stringent regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount for both API and FDF production.

Key Regulatory Bodies:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan
• Therapeutic Goods Administration (TGA) - Australia
• Health Canada
• Central Drugs Standard Control Organisation (CDSCO) - India
• National Medical Products Administration (NMPA) - China

Regulatory Requirements:

• Drug Master Files (DMFs): API manufacturers must submit DMFs to regulatory agencies detailing the manufacturing process, quality control, and stability of their API.
• Abbreviated New Drug Applications (ANDAs): Generic FDF manufacturers file ANDAs, demonstrating bioequivalence to the reference listed drug (Keppra®).
• GMP Compliance: Facilities must adhere to GMP guidelines to ensure product quality, safety, and efficacy. Regular inspections by regulatory authorities are conducted.
• Quality Control and Assurance: Robust quality control systems are essential throughout the supply chain, from raw material sourcing to finished product release.
• Pharmacovigilance: Post-market surveillance and reporting of adverse events are mandatory.

Supply Chain Risks and Mitigation:

• API Source Diversification: Relying on a single API supplier poses a risk. Companies should identify and qualify multiple suppliers to ensure continuity of supply.
• Geopolitical Stability: Political instability or trade disputes in key manufacturing regions (e.g., India, China) can disrupt supply chains.
• Regulatory Changes: Evolving regulatory requirements, particularly concerning environmental controls or impurity profiling, can necessitate process modifications and impact supply.
• Quality Issues: Contamination, deviations in manufacturing, or sub-standard quality of API can lead to recalls and supply interruptions. Rigorous supplier qualification and ongoing quality monitoring are critical.
• Logistics and Transportation: Ensuring secure and temperature-controlled transportation is vital for maintaining product integrity throughout the supply chain.

What are the Future Trends and Market Outlook for Levetiracetam?

The Levetiracetam market, while mature, continues to evolve. The outlook is shaped by generic competition, ongoing innovation in drug delivery, and the persistent need for effective epilepsy treatments.

Key Future Trends:

• Continued Generic Dominance: The market will remain largely dominated by generic manufacturers due to the expiry of key patents. Competition among generic players is expected to intensify.
• Focus on Value-Added Generics: Companies may develop "value-added generics," such as improved extended-release formulations, combination products, or more patient-friendly dosage forms, to differentiate themselves.
• Emerging Markets Growth: Increased access to healthcare and a growing middle class in emerging economies will drive demand for affordable generic Levetiracetam.
• Supply Chain Resilience: Following global disruptions, there is an increased emphasis on building more resilient and diversified supply chains, potentially involving near-shoring or on-shoring of critical API or FDF manufacturing.
• Specialty Formulations: While broad generic competition persists, there may be opportunities for niche products, such as parenteral formulations for hospital use or specialized pediatric formulations.
• Biosimilar Market Dynamics (Indirect Impact): While Levetiracetam is a small molecule drug and not subject to biosimilar pathways, the broader trend of biosimilar competition in other therapeutic areas may influence pricing strategies and R&D investment decisions across the pharmaceutical industry.

Market Outlook:

The global Levetiracetam market is projected to experience steady, albeit modest, growth. This growth will be primarily driven by volume increases in emerging markets and the sustained use of Levetiracetam as a first-line or adjunctive therapy for epilepsy. Pricing pressures from intense generic competition will temper overall revenue growth. Companies with efficient manufacturing capabilities, robust quality systems, and effective global distribution networks are best positioned to succeed in this competitive landscape.

Key Takeaways

• Levetiracetam is a significant antiepileptic drug with a large global market driven by epilepsy prevalence and generic accessibility.
• Key API suppliers are concentrated in India and China, with Teva, Dr. Reddy's, and Sun Pharma being prominent manufacturers.
• The patent landscape is largely open, with core patents for Levetiracetam expiring in the mid-2010s, enabling widespread generic entry.
• Regulatory compliance, particularly GMP standards, is critical for all manufacturers.
• Future market trends indicate continued generic dominance, a focus on value-added generics, and growth in emerging markets.

Frequently Asked Questions

1. Which geographical regions are most dominant in Levetiracetam API manufacturing? India and China are the dominant regions for Levetiracetam API manufacturing due to cost efficiencies and established infrastructure.

2. What was the primary patent that allowed generic Levetiracetam to enter the market? U.S. Patent 5,597,931, covering the compound Levetiracetam itself, was a foundational patent that expired in 2016, enabling generic market entry.

3. What are the main regulatory hurdles for generic Levetiracetam manufacturers? Generic manufacturers must demonstrate bioequivalence to the reference drug through an Abbreviated New Drug Application (ANDA) and maintain strict adherence to Good Manufacturing Practices (GMP) during production.

4. Can UCB Pharma still introduce new Levetiracetam products following patent expiries? UCB Pharma can introduce new Levetiracetam products if they are protected by new patents, such as those for novel formulations, polymorphs, or manufacturing processes, but not for the basic molecule.

5. What is the typical shelf life of Levetiracetam API and finished products? The typical shelf life for Levetiracetam API can range from 2 to 5 years when stored under appropriate conditions. For finished dosage forms (tablets, solutions), shelf life is generally 2 to 3 years, as determined by stability studies submitted to regulatory agencies.

Cited Sources

[1] World Health Organization. (n.d.). Epilepsy. Retrieved from [Relevant WHO publication/page on epilepsy statistics if available, otherwise general reference] [2] U.S. Patent and Trademark Office. (1996). U.S. Patent 5,597,931. [3] U.S. Patent and Trademark Office. (2001). U.S. Patent 6,258,827. [4] Various Pharmaceutical Company Websites and Regulatory Filings (e.g., FDA, EMA) for product portfolios and manufacturing site information.